| Field | Specification |
|---|---|
| Target | |
| Species | |
| Applications | |
| Tag | |
| Expression system | |
| Expression region | |
| Molecular weight | |
| Purity | |
| Biological activity | |
| Endotoxin level | |
| Animal origin-free | |
| Reconstitution | |
| Formulation | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Recombinant Human TPO Protein (thrombopoietin) is expressed in human cells and supplied as a glycosylated monomer. It is tag-free, animal-free and xeno-free, and is lyophilized from a 0.2 µm-filtered PBS solution without carrier protein, with purity >95% by SDS-PAGE and endotoxin <0.5 EU/µg.
TPO is used for HSPC survival and expansion in SCF/FLT3L-containing systems, for megakaryocytic commitment and maturation, for proplatelet and platelet-biogenesis studies and for MPL signaling research. Expression in human cells supports glycosylation of the full-length protein, activity is confirmed in Mo7e cells, and four peer-reviewed studies report use of this TPO.
Expression system: Human cells · Tag-free · Animal-free
Scientific Background
Thrombopoietin is a heavily glycosylated cytokine made mainly by the liver. It is the principal ligand of the MPL receptor on hematopoietic stem/progenitor cells and megakaryocytic progenitors, where it activates JAK2/STAT5, MAPK and PI3K signaling.
In culture, TPO helps maintain and expand HSPCs and promotes the growth, commitment and maturation of megakaryocytes toward platelet formation. What it does at a given point depends on the developmental stage, the cytokines used with it and the culture format.
Research Applications
TPO is used from early HSPC culture through megakaryocyte maturation, usually with SCF and FLT3 Ligand at early stages. The table shows typical placements; it is a planning guide, not a universal protocol.
| Application | Role of TPO | Companion context | Suggested readouts |
|---|---|---|---|
| Cord-blood CD34+ culture | Stem/progenitor maintenance | SCF and FLT3L, plus protocol-specific factors | Expansion, CD34/CD38/CD90, CFU, engraftment |
| hPSC hematopoietic differentiation | Post-hemogenic progenitor support | SCF, FLT3L and lineage-stage cytokines | CD43, CD45, CD34, multilineage potential |
| Megakaryocyte differentiation | Commitment and maturation | SCF early; later cytokine withdrawal by protocol | CD41, CD42b, polyploidy, proplatelets |
| Mo7e bioassay | Dose-dependent proliferation | Defined assay medium | Proliferation and relative potency |
Planning considerations
- Confirm the responsive cell stage and MPL receptor context.
- Take conditions from published or in-house validated work and titrate TPO for the cell source and endpoint.
- Control timing, medium, matrix and companion factors.
- Include vehicle/no-factor and pathway-response controls, and measure phenotype and function rather than cell number alone.
Protein Specifications
| Target | TPO |
|---|---|
| Alternative names | Thrombopoietin |
| Species | Human |
| Expression system | Human cells |
| Structure | Glycosylated monomer |
| Protein family | Hematopoietic cytokine |
| Tag | Tag-free |
| Animal origin | Animal-free / Xeno-free |
| Molecular weight | 80–85 kDa. Refer to the lot-specific Certificate of Analysis (CoA) for lot data. |
| Purity | >95% by SDS-PAGE |
| Endotoxin level | <0.5 EU/µg |
| Formulation | Lyophilized from a 0.2 µm-filtered solution in PBS without carrier protein |
| Form | Lyophilized |
| Biological activity | Stimulation of human Mo7e cell proliferation |
| EC50 | 0.36–0.53 ng/mL |
| Applications | Stem Cell Differentiation, Immunotherapy, Hematopoietic Differentiation, Cell Proliferation, Colony-Forming Unit Assay, Cell Signaling Studies |
Biological Activity & Quality Control
Activity is determined as proliferation of human Mo7e cells in response to TPO, giving an EC50 of 0.36–0.53 ng/mL in the manufacturer's assay.
Lot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.
Reconstitution
- Briefly centrifuge the vial before opening.
- Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.
- Mix gently and prepare single-use aliquots.
- Avoid repeated freeze–thaw cycles.
Storage & Shipping
| Storage | As supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles. |
|---|---|
| Shipping | Please contact us to confirm shipping conditions for this product. |
Selected References
- de Sauvage FJ, Hass PE, Spencer SD, et al. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533-538. 10.1038/369533a0
- Lok S, Kaushansky K, Holly RD, et al. (1994) Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565-568. 10.1038/369565a0
Safety & Handling
Handle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.
For research use only. Not for diagnostic or therapeutic use.
Can't Find What You're Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Zhu S, et al. (2025) TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors. Exp Hematol Oncol 14:26. 10.1186/s40164-025-00613-y
Zhang Y, et al. (2024) Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy. Cell Rep Methods 4:100843. 10.1016/j.crmeth.2024.100843
Xie H, et al. (2022) Transient Inhibition of the JNK Pathway Promotes Human Hematopoietic Stem Cell Quiescence and Engraftment. Stem Cells Transl Med 11:597-603. 10.1093/stcltm/szac019
Xiao X, et al. (2019) Targeting JNK pathway promotes human hematopoietic stem cell expansion. Cell Discov 5:2. 10.1038/s41421-018-0072-8